A genome‐wide CRISPR screen identifies FBXO42 involvement in resistance toward MEK inhibition in NRAS‐mutant melanoma

NRAS mutations are the most common alterations among RAS isoforms in cutaneous melanoma, with patients harboring these aggressive tumors having a poor prognosis and low survival rate. The main line of treatment for these patients is MAPK pathway‐targeted therapies, such as MEK inhibitors, but, unfor...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:Pigment Cell Melanoma Res
मुख्य लेखकों: Nagler, Adi, Vredevoogd, David W., Alon, Michal, Cheng, Phil F., Trabish, Sophie, Kalaora, Shelly, Arafeh, Rand, Goldin, Victoria, Levesque, Mitchell P., Peeper, Daniel S., Samuels, Yardena
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: John Wiley and Sons Inc. 2019
विषय:
Original Articles
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC7383499/
https://ncbi.nlm.nih.gov/pubmed/31549767
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/pcmr.12825
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन